<DOC>
	<DOCNO>NCT01093365</DOCNO>
	<brief_summary>Smokers schizophrenia difficulty quit smoking smoker without mental disorder . Varenicline ( Champix ) new stop smoking medication unique mechanism action . It nicotine-like drug addictive associate health risk tobacco smoke . Varenicline ( VAR ) bind site brain call nicotine receptor play important role nicotine dependence . People schizophrenia difficulty concentrate remembering . Scientists believe people schizophrenia use smoke remedy cognitive problem . We test VAR see improve cognitive problem smoker schizophrenia comparison non-mentally ill smoker determine whether people schizophrenia get direct benefit nicotine-like drug . It hypothesize VAR ( comparison placebo ) reduce aspect cognitive impairment smoker nonsmoker schizophrenia .</brief_summary>
	<brief_title>Effect Varenicline Cognitive Function Cigarette Smokers With Schizophrenia</brief_title>
	<detailed_description>Schizophrenia characterize deficit neurocognitive function , include executive function , attention , spatial verbal memory . Central nicotinic acetylcholine receptor ( nAChR ) dysregulated schizophrenia . It show neurocognitive deficit schizophrenia improve administration nicotine , nicotinic agonist cigarette smoke . Hence , believe cigarette smoking may remedy cognitive deficit schizophrenia fact person schizophrenia may `` self-medicating '' tobacco counter cognitive problem . The prevalence rate cigarette smoke person schizophrenia high general population ( 58-88 % vs. 25 % respectively ) . This population also nicotine dependence rate around 80 % high relapse rate smoking cessation . Additionally leading cause medical problem death people schizophrenia tobacco addiction . Research address problem smoking schizophrenia great importance . Varenicline ( VAR ) , α4β2 nAChR partial agonist , approve smoking cessation , mimic effect nicotine stimulate nAChRs , release sufficient dopamine order reduce crave withdrawal effect . This study follow four group subject ( N=40 ) receive neuropsychological psychiatric test three consecutive session ( smoke satiation , abstinence reinstatement ) separate least one week 3 week . The group : 1. cigarette smoker schizophrenia ( N=10 ) , 2. non-smokers schizophrenia ( N=10 ) , 3. healthy cigarette smoking control ( N=10 ) , 4. non-smoking control ( N=10 ) . All group age- sex- match . Pre-treatment varenicline ( VAR ) placebo start Day 1 test session follow : 1 ) 0.0 mg/day 2 ) 0.5 mg twice daily 3 ) 1 mg twice daily 3 day . Testing day separate least 1 week apart rule medication carry-over effect . If nicotinic acetylcholine receptor stimulate result dopamine release improve neurocognitive function without induce deleterious health effect may benefit person schizophrenia smoke tobacco .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>I ) For subject Age 1855 Estimated IQ ≥80 use Shipley scale Capable give informed consent Not take form nicotine replacement therapy II ) Additional inclusion criterion smoker : 1 . Nontreatment seek cigarette smoker : A score 5 high Fagerstrom Test Nicotine Dependence ( FTND ) Self report smoke least 10 cigarette per day measure Weekly Smoking Inventory ( NOTE : Cigarette smoke verified Smokerlyzer® test , cut 10 ppm plasma cotinine level ≥150 ng/ml ) 2 . Cigarette smoker Schizophrenia : Diagnosis schizophrenia/schizoaffective disorder ( confirm SCID DSMIV ) Stable remission positive symptom psychosis judge score &lt; 70 The Positive Negative Syndrome Scale ( PANSS ) schizophrenia psychiatric evaluation Receiving stable dose antipsychotic medication ( ) past month III ) Additional inclusion criterion healthy smoker nonsmoker : No diagnosis Axis I psychiatric disorder ( Except past history major depression ) For subject Substance abuse cigarette smoking . History alcohol/drug abuse 3 month study enrollment Hypersensitivity varenicline ( Champix ) Use opioids ( meperidine , oxycodone , methadone , etc ) . A history renal insufficiency Gastrointestinal problem include irritable bowel syndrome Exposure chemotherapy A history dementia neurological illness like epilepsy medical condition know significantly influence neurocognitive function Inability learn neuropsychological task train session Failure demonstrate deficit least 0.5 standard deviation average level nonpsychiatric control performance Visuospatial Working Memory ( VSWM ) task Pregnancy Nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Champix</keyword>
	<keyword>Chantix</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Nicotinic receptor</keyword>
	<keyword>Dopamine</keyword>
	<keyword>Acetylcholine</keyword>
	<keyword>Cigarette</keyword>
	<keyword>Smoking</keyword>
	<keyword>Tobacco</keyword>
	<keyword>Executive function</keyword>
	<keyword>Working memory</keyword>
	<keyword>Verbal memory</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>Neuropsychological function</keyword>
</DOC>